Abstract:Background While the past decades have seen an explosion of innovation in immunotherapies, most have failed in their clinical studies. One of the barriers encountered across these trials is that despite demonstrated cytoxicity, tumor immune evasion renders these treatments ineffective. Glioblastoma (GBM) is one of these tumors where experimental immunotherapeutics have continued to fail. The median survival of GBM remains at 15 months with the primary treatment being surgical resection, radiation, and chemotherapeutic over the past decade. To breach this stalemate, we require new therapeutics that both can target tumor immune evasion and can balance efficacy with toxicity. Our lab previously developed a subcutaneous autologous tumor vaccine utilizing a phagocytosis-stimulating ligand mannan anchored to irradiated (IR) tumor cells with the adjuvants toll-like receptor (TLR) agonists and immunostimulant anti-CD40 antibody (collectively abbreviated as MBTA). This regime allowed recognition of tumors resulting in a coordinated innate and adaptive immune response in both prophylactic and therapeutic studies with colon carcinoma, breast tumor, and GBM mouse models. The aim of our study was to generate a dendritic cell (DC) vaccine utilizing this strategy. Methods To assess if MBTA anchored GBM cells could mature DCs in-vitro, we harvested bone-marrow DCs (BMDCs) from mice and co-cultured them with MBTA GBM cells for 24 hours. Analysis was performed by flow cytometry and ELISA to confirm maturation markers and DC phenotype. To assess if MBTA DCs could protect against tumor metastasis, we utilized a melanoma (B16) prophylactic model by vaccinating mice 1 week before tail vein melanoma challenge. Results We found robust up-regulation of co-stimulatory molecules CD40, CD80 and CD86 and preferential upregulation of MHCI in the MBTA group with ELISA analysis demonstrating MBTA DCs significantly upregulated Type 1 cytokines (TNFa and IL-6) and limited regulatory cytokine (IL-10) secretion across GBM cell lines. Mice vaccinated with MBTA DCs had a significant decrease in lung metastasis compared to controls with lung immunohistochemistry demonstrating robust perivascular lymphocytic infiltration. Currently, we are working on demonstrating this efficacy in a glioblastoma model. Conclusions Collectively our results demonstrate that MBTA is an effective strategy to mature and load tumor antigens onto DCs ex-vivo. It has efficacy as a DC vaccine to prevent melanoma metastasis and potential as a glioblastoma DC vaccine. Acknowledgements The authors acknowledge the NCI-CCR affiliated staff for their assistance with animal housing and the NCI CCR Flow Cytometry Core Members for their expertise in flow cytometry Ethics Approval The National Cancer Institute (NCI) Animal Use and Care Committees approved the present study under NOB-010 and NOB-016.

An Interesting Design of Fusion Protein to Kill Glioma Cell Line of U-87 MG Cells

Tumor Microenvironment Targeting System for Glioma Treatment Via Fusion Cell Membrane Coating Nanotechnology.

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

Inhibition of Cell Proliferation, Migration and Invasion by A Glioma-Targeted Fusion Protein Combining the P53 C Terminus and Mdm2-Binding Domain

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

The Antitumor Effect of TAT-DCF1 Peptide in Glioma Cells

Targeted Killing Effect of IL-13 Diphtheria Toxin Fusion Protein and DT_(389)-hIL13-13E13K

Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma

Efficacy of Antiangiogenic Targeted Immunotoxin DTAT and DTATEGF Against Glioblastoma Multiforme.

A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression

Immu-61. The Last Of Us: A Fungi Based Dendritic Cell Vaccine

Novel Molecular Multilevel Targeted Antitumor Agents

A Pentapeptide Enabled AL3810 Liposome-Based Glioma-Targeted Therapy with Immune Opsonic Effect Attenuated.

Selection of DNA Aptamers Against Glioblastoma Cells with High Affinity and Specificity

Glioma Targeting Peptide in Combination with the P53 C Terminus Inhibits Glioma Cell Proliferation in Vitro

Construction of Eukaryotic Expression Plasmid Pegfp-N3-m-il-2(88 Arg,125 Ala) and Its Effects on Glioma Cell Line U87

Biomimetic Nanocomposites Camouflaged with Hybrid Cell Membranes for Accurate Therapy of Early-Stage Glioma.

RGD Peptide Conjugation Results in Enhanced Antitumor Activity of PD0325901 Against Glioblastoma by Both Tumor-Targeting Delivery and Combination Therapy.

Preparation of Molecular Targeting Toxins Against Glioma and Study on Their Biological Characters

Tumor microenvironment targeting for glioblastoma multiforme treatment via hybrid cell membrane coating supramolecular micelles

Efficient Delivery of Lomitapide Using Hybrid Membrane‐Coated Tetrahedral DNA Nanostructures for Glioblastoma Therapy